For example, the proportion of patients receiving the time-critical thrombolysis infusion (tPA) and the modified Rankin Scale (mRS) has been used consistently across most TeleStroke studies as the clinical effectiveness measure; however, tPA infusion is only applicable to ischaemic stroke patients. This evidence concerns the gene PLAT and ischemic stroke.